Job Recruitment Website - Recruitment portal - Brief introduction of Nanjing haichen pharmaceutical industry

Brief introduction of Nanjing haichen pharmaceutical industry

The company is located in Qixia in the east, Zhongshan in the south and the Yangtze River in the north, with beautiful environment and convenient transportation. The first phase of the project covers an area of 108 mu with a total investment of 98 million yuan. According to the requirements of national GMP, the company has established advanced and modern workshops for freeze-dried powder injection, cephalosporin (sub-packaging), solid preparations and raw materials, advanced production equipment, strict quality management system and excellent management team, which has enabled the company to develop and become a peer.

Haichen Pharmaceutical currently has more than 300 employees, 80% of whom have professional backgrounds in medicine, chemistry, bioengineering and other related disciplines. Through the standardized training system, the company plans and manages employees' career, gives full play to employees' potential and promotes the common development of employees and enterprises. Haichen Pharmaceutical Co., Ltd. has a modern new drug research center, a research and development team composed of doctors, masters and other professional and technical personnel, and has extensive project cooperation with famous medical colleges and scientific and technological institutions at home and abroad. The company has successfully developed more than 30 national new drugs such as gatifloxacin, sparfloxacin, amlodipine besylate, sildenafil (Viagra), exetamine and torasemide. More than 10 new products can be launched every year on average, which provides a strong guarantee for the sustainable development of enterprises. Haichen Pharmaceutical Co., Ltd. has a perfect drug sales system, with terminal networks all over most provinces and marketing agencies all over major cities in China. It has nearly 1,000 large and medium-sized target hospitals and nearly 200 key commercial distribution units. The company will introduce more than 30 new drug varieties such as gatifloxacin for injection, ganciclovir sodium for injection, cefminox sodium for injection, cefamandole sodium for injection, cefpiramide for injection, thymopentin for injection and omeprazole sodium for injection, and the company will follow up.